Xerostomia Market Size was approximately USD XX Million in 2022, estimates DelveInsight

"The Xerostomia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Xerostomia pipeline products will significantly revolutionize the Xerostomia market dynamics"

The Xerostomia market report provides current treatment practices, Xerostomia emerging drugs, market share of individual therapies, and current and forecasted 7MM a Xerostomia market size from 2019 to 2032. The report also covers current Xerostomia treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Xerostomia Market Research Report
• The increase in Xerostomia market size is a direct consequence of the increasing prevalent population of Xerostomia patients in the 7MM.
• As per the European Association of Oral Medicines, Xerostomia occurs more commonly in females than males.
• The leading companies working in the Xerostomia Market include SunBio Inc., NAMSA, Rudacure, Camurus AB, Sunstar Americas, MeiraGTx LLC, Pierre Fabre Medicament, Saliwell Ltd., 3M, TorreyPines Therapeutics, GlaxoSmithKline, Parion Sciences, Invado Pharmaceuticals, and others.
• Promising Xerostomia Pipeline Therapies in the various stages of development include MucoPEG, XER2020, Electrostimulation, 552-02, AAV2hAQP1: 1 x 10^11 vg/gland (single gland), and others.
• September 2023: Novartis Pharmaceuticals announced a study of Phase 2 Clinical trials for Ianalumab. This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments.
• October 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Deucravacitinib. The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Discover more about therapies set to grab major Xerostomia Market Share @ Xerostomia Market Size- https://www.delveinsight.com/report-store/xerostomia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Xerostomia Overview
Xerostomia, commonly known as dry mouth, is a condition characterized by a reduced flow of saliva in the mouth due to abnormal function of salivary glands, leading to complaint of oral dryness. Saliva plays a crucial role in maintaining oral health by helping with digestion, cleansing the mouth, and preventing tooth decay.

Xerostomia Epidemiology Segmentation in the 7MM
• Total Xerostomia Prevalent Cases
• Xerostomia Gender-specific cases
• Xerostomia Diagnosed Prevalent Cases
• Xerostomia Treated Cases
• Xerostomia Age-specific cases

Download the report to understand which factors are driving Xerostomia Epidemiology Trends @ Xerostomia Epidemiological Insights- https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Xerostomia Treatment Market
The Xerostomia Treatment Market, a rapidly evolving sector in the healthcare industry, focuses on addressing the challenges posed by xerostomia, commonly known as dry mouth syndrome. This condition, characterized by reduced saliva production, can lead to various oral health issues and discomfort for individuals. The market for xerostomia treatment has witnessed substantial growth due to the rising prevalence of dry mouth among the aging population, cancer patients undergoing radiation therapy, and individuals using medications that cause dry mouth as a side effect.

Xerostomia Market Landscape
The Xerostomia market products and treatments has been experiencing growth due to the rising awareness of oral health, an aging population, and a higher prevalence of associated conditions such as diabetes and autoimmune disorders.

To know more about Xerostomia Treatment options, visit @ Xerostomia Drugs- https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Xerostomia Market Dynamics
The Xerostomia market dynamics is anticipated to change in the coming years. Key players, such as Lubris BioPharma, MeiraGTx, and others are involved in developing drugs for Xerostomia.

Xerostomia Marketed Drugs
• Pilocarpine and Cevimeline
The two systemic agents that are approved therapies for xerostomia by the US Food and Drug Administration are oral pilocarpine and cevimeline. Pilocarpine is a nonselective muscarinic agonist and parasympathetic agent. The recommended starting dose is 5 mg for a maximum of 30 mg daily. Pilocarpine specifically can diminish dry mouth in patients who have undergone radiation therapy to the head and neck.
Cevimeline is a muscarinic agonist that is selective for M1 and M3 receptors, which are located in the lacrimal and salivary glands. It has fewer side effects than pilocarpine because it does not affect M2 receptors. Standard dosing is 30 mg three times daily for at least 3 months.

Xerostomia Emerging Drugs
• AAV2hAQP1- MeiraGTx
AAV2hAQP1 is being developed to treat radiation-induced xerostomia (RIX) by increasing water conduction in the salivary glands damaged by radiation therapy. This gene therapy product candidate works by introducing a water conducting channel into the remaining epithelial cells of these damaged glands. Recently, in December 2021, MeiraGTx announced Positive Preliminary Data from the AQUAx Phase I Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia. These results point to the potential for AAV-hAQP1 to be a disease-modifying one-time treatment for this large population of patients who currently have no effective treatment options for this devastating and intractable condition.

• LBS-020- Lubris Biopharma
LBS-020 being developed by Lubris Pharma is a recombinant lubricin and a glycoprotein stimulant. Lubricin is a large endogenous complex glycoprotein that binds to and protects tissue surfaces from friction. LBS-020 is still in the preclinical phase.

Learn more about the Xerostomia Pipeline Therapies in clinical trials @ Xerostomia Market Landscape- https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Xerostomia Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Xerostomia Companies- SunBio Inc., NAMSA, Rudacure, Camurus AB, Sunstar Americas, MeiraGTx LLC, Pierre Fabre Medicament, Saliwell Ltd., 3M, TorreyPines Therapeutics, GlaxoSmithKline, Parion Sciences, Invado Pharmaceuticals, and others.
• Xerostomia Pipeline Therapies- MucoPEG, XER2020, Electrostimulation, 552-02, AAV2hAQP1: 1 x 10^11 vg/gland (single gland), and others
• Xerostomia Market Dynamics: Xerostomia Market Drivers and Barriers
• Xerostomia Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Xerostomia Drugs in development @ Xerostomia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Report Introduction
2. Xerostomia Executive Summary
3. Xerostomia Market Overview at a Glance
4. Xerostomia Market Disease Background and Overview
5. Xerostomia Epidemiology Methodology
6. Xerostomia Epidemiology and Patient Population
7. Xerostomia: Country-Wise Epidemiology
8. Xerostomia Marketed Products
10. Xerostomia Emerging Therapies
11. Xerostomia Market Size
12. 7MM Xerostomia: Country-Wise Market Analysis
13. Xerostomia SWOT Analysis
14. Xerostomia Market Access and Reimbursement
15. Appendix
16. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.